Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)
China · Delayed Price · Currency is CNY 28.10
-1.25 (-4.26%)
At close: Feb 2, 2026
SHE:002773 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,664 | 4,451 | 3,957 | 3,388 | 3,605 | 3,294 |
Other Revenue | 1.49 | 1.49 | 0.63 | 0.64 | 0.19 | 1.27 |
| 4,665 | 4,453 | 3,957 | 3,389 | 3,605 | 3,295 | |
Revenue Growth (YoY) | 6.76% | 12.51% | 16.77% | -6.00% | 9.40% | 1.17% |
Cost of Revenue | 474.6 | 469.43 | 438.84 | 391.66 | 355.66 | 330.22 |
Gross Profit | 4,191 | 3,983 | 3,519 | 2,997 | 3,250 | 2,965 |
Selling, General & Admin | 2,241 | 2,117 | 1,943 | 1,710 | 1,786 | 1,892 |
Research & Development | 571.71 | 579.71 | 421.68 | 374 | 1,008 | 1,676 |
Other Operating Expenses | 52.91 | 53.43 | 52.75 | 48.47 | 51.08 | 45.92 |
Operating Expenses | 2,865 | 2,751 | 2,418 | 2,133 | 2,843 | 3,613 |
Operating Income | 1,326 | 1,232 | 1,101 | 864.46 | 407 | -647.52 |
Interest Expense | - | - | - | - | - | -0.5 |
Interest & Investment Income | 95.53 | 110.18 | 97.53 | 83.14 | 61.55 | 59.97 |
Currency Exchange Gain (Loss) | -0.16 | -0.16 | 0.16 | 0.34 | 0.12 | 2.24 |
Other Non Operating Income (Expenses) | -7.73 | 0.81 | -1.39 | -0.65 | -0.94 | -0.58 |
EBT Excluding Unusual Items | 1,413 | 1,343 | 1,197 | 947.29 | 467.73 | -586.4 |
Impairment of Goodwill | - | - | - | - | -214.84 | - |
Gain (Loss) on Sale of Investments | -0.39 | -1.06 | -0.83 | - | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.01 | - | - | - |
Asset Writedown | -1.61 | -1.14 | -0.52 | -0.24 | -0.67 | -2.4 |
Other Unusual Items | 11.5 | 11.5 | 38.26 | 83.25 | 141.19 | 69.28 |
Pretax Income | 1,423 | 1,353 | 1,234 | 1,030 | 393.42 | -519.51 |
Income Tax Expense | 189.57 | 175.53 | 202.79 | 164.49 | -27.66 | -249.66 |
Earnings From Continuing Operations | 1,233 | 1,177 | 1,031 | 865.81 | 421.08 | -269.85 |
Minority Interest in Earnings | 17.18 | 14.22 | 13.64 | 30.86 | 0 | - |
Net Income | 1,250 | 1,191 | 1,045 | 896.67 | 421.08 | -269.85 |
Net Income to Common | 1,250 | 1,191 | 1,045 | 896.67 | 421.08 | -269.85 |
Net Income Growth | 4.80% | 14.02% | 16.52% | 112.94% | - | - |
Shares Outstanding (Basic) | 919 | 916 | 916 | 915 | 915 | 870 |
Shares Outstanding (Diluted) | 919 | 916 | 916 | 915 | 915 | 870 |
Shares Change (YoY) | 0.16% | -0.01% | 0.16% | -0.05% | 5.16% | -0.34% |
EPS (Basic) | 1.36 | 1.30 | 1.14 | 0.98 | 0.46 | -0.31 |
EPS (Diluted) | 1.36 | 1.30 | 1.14 | 0.98 | 0.46 | -0.31 |
EPS Growth | 4.64% | 14.04% | 16.33% | 113.04% | - | - |
Free Cash Flow | 1,344 | 1,252 | 1,080 | 569.95 | -75.3 | -348.53 |
Free Cash Flow Per Share | 1.46 | 1.37 | 1.18 | 0.62 | -0.08 | -0.40 |
Dividend Per Share | 0.600 | 0.600 | 0.380 | 0.150 | 0.100 | 0.100 |
Dividend Growth | 57.89% | 57.89% | 153.33% | 50.00% | - | -64.29% |
Gross Margin | 89.83% | 89.46% | 88.91% | 88.44% | 90.14% | 89.98% |
Operating Margin | 28.42% | 27.68% | 27.81% | 25.51% | 11.29% | -19.65% |
Profit Margin | 26.80% | 26.75% | 26.40% | 26.46% | 11.68% | -8.19% |
Free Cash Flow Margin | 28.82% | 28.13% | 27.28% | 16.82% | -2.09% | -10.58% |
EBITDA | 1,561 | 1,462 | 1,322 | 1,021 | 554.33 | -529.02 |
EBITDA Margin | 33.46% | 32.82% | 33.40% | 30.11% | 15.38% | -16.05% |
D&A For EBITDA | 235.25 | 229.14 | 221 | 156.12 | 147.33 | 118.5 |
EBIT | 1,326 | 1,232 | 1,101 | 864.46 | 407 | -647.52 |
EBIT Margin | 28.42% | 27.68% | 27.81% | 25.51% | 11.29% | -19.65% |
Effective Tax Rate | 13.32% | 12.98% | 16.43% | 15.96% | - | - |
Revenue as Reported | 4,665 | 4,453 | 3,957 | 3,389 | 3,605 | 3,295 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.